Aytu Biopharma Inc Stock Price, News & Analysis

Aytu BioPharma (NASDAQ:AYTU) announced a strategic transaction with Acerus Pharmaceuticals, whereby Acerus will acquire all U.S. rights to Natesto. Aytu will receive $7.5M in total, paid in $250,000 monthly installments over 30 months. The deal enables Aytu to focus on pediatric and ADHD therapeutics following their recent merger with Neos Therapeutics. This transition supports Aytu's strategy to enhance shareholder value by concentrating resources on their expanded portfolio of pediatric products.

Aytu BioScience has successfully merged with Neos Therapeutics, becoming Aytu BioPharma. The newly combined company boasts an annual revenue of $100 million, with an anticipated $15 million in cost synergies for 2022. This merger enhances Aytu's position in pediatrics and specialty care markets. Former Neos board members Beth P. Hecht and Gerald McLaughlin join Aytu's board as part of the transition. The merger concluded following approval at shareholder meetings on March 18, 2021, positioning Aytu for future growth and shareholder value enhancement.

Aytu BioScience announced promising results from a pilot study using its Healight technology on mechanically ventilated COVID-19 patients. The study showed that endotracheal ultraviolet A (UVA) light therapy significantly reduced SARS-CoV-2 viral load by over 99% and improved clinical severity scores. Conducted on five patients, the treatment was well tolerated with no serious adverse effects reported. Aytu plans to further collaborate with the FDA and explore additional applications beyond COVID-19.

Aytu BioScience (NASDAQ:AYTU) has announced that CEO Josh Disbrow will present at three investor conferences in March 2021. The events include:

• Cowen 41^st Annual Healthcare Conference: March 3, 2021, at 10:20 a.m. ET.
• H.C. Wainwright Global Life Sciences Conference: Pre-recorded chat available March 9, 2021, at 7:00 a.m. ET.
• Oppenheimer 31^st Annual Healthcare Conference: March 16, 2021, at 4:30 p.m. ET.

These presentations can be accessed on the Aytu website.

Aytu BioScience announced a definitive merger with Neos Therapeutics, creating a combined specialty pharmaceutical entity with projected revenues of $100 million. For Q2 2021, Aytu reported net revenues of $15.1 million, a significant increase from $13.5 million in Q1 2021, with the Consumer Health division achieving an all-time revenue high of $7.9 million. The Rx division revenue rose 24% sequentially to $7.2 million. Despite a net loss of $9.5 million, Aytu maintains a strong cash position of $62.3 million, indicating financial stability as they approach the merger's closing in Q2 2021.

Aytu BioScience (NASDAQ:AYTU) and Neos Therapeutics (NASDAQ:NEOS) have scheduled special stockholder meetings for March 18, 2021, to discuss their proposed merger. The record date for eligibility to vote is February 5, 2021. Upon closing, the new entity will be rebranded as Aytu Biopharma, Inc., and will retain the AYTU ticker symbol on Nasdaq. Both companies’ Boards recommend stockholders vote 'FOR' the merger proposals. The joint proxy statement/prospectus will be mailed on February 12, 2021, providing further details on the merger process.

Aytu BioScience, Inc. (NASDAQ:AYTU) announced a conference call to discuss its operational results for the fiscal second quarter ending December 31, 2020, scheduled for February 11, 2021, at 4:30 PM ET. During this call, the company will highlight its quarterly accomplishments and future business strategies. Aytu markets several FDA-approved products, including Natesto, ZolpiMist, and Tuzistra XR, along with a range of pediatric medications. Additionally, Aytu is actively involved in COVID-19 testing and has licensed Healight™ technology for potential respiratory treatments.

Aytu BioScience, a specialty pharmaceutical company, announced the completion of a safety study for its Healight™ ultraviolet A light catheter technology. This study focused on critically ill COVID-19 patients on mechanical ventilation in the U.S. The safety data will be presented to the FDA for potential treatment of SARS-CoV-2. CEO Josh Disbrow highlighted this as a significant milestone, aiming for continued FDA discussions. This technology is designed to reduce viral and bacterial loads, with promising pre-clinical findings paving the way for human trials.

Aytu BioScience, a specialty pharmaceutical company, announced its presentation at the LD Micro Virtual Investor Conference on December 15, 2020, at 2:20 PM ET. This conference features a new format, allowing each company a 10-minute presentation followed by a 10-minute Q&A session with investors and analysts. Aytu's portfolio includes unique FDA-approved products addressing significant patient needs in primary care and pediatrics. For more details, visit the webcast.